ARA-290 is a synthetic peptide derived from erythropoietin, but unlike erythropoietin, it does not stimulate red blood cell production. Instead, it acts as a selective agonist for the Innate Repair Receptor (IRR), which plays a role in tissue protection and repair. ARA-290 has shown promise in preclinical and clinical studies for treating conditions like diabetic neuropathy, sarcoidosis-related small fiber neuropathy, and potentially other neuropathic pain conditions.
ARA-290 is a peptide derived from erythropoietin (EPO) that has been studied for its potential role in reducing inflammation and protecting nerve and tissue health. Research suggests it may support recovery from nerve-related discomfort, improve insulin sensitivity, and promote overall cellular repair. ARA-290 is often explored in studies on chronic inflammation, nerve regeneration, and metabolic health.
